1. KIBRA repairs synaptic plasticity and promotes resilience to tauopathy-related memory loss
- Author
-
Kauwe, Grant, Pareja-Navarro, Kristeen A., Yao, Lei, Chen, Jackson H., Wong, Ivy, Saloner, Rowan, Cifuentes, Helen, Nana, Alissa L., Shah, Samah, Li, Yaqiao, Le, David, Spina, Salvatore, Grinberg, Lea T., Seeley, William W., Kramer, Joel H., Sacktor, Todd C., Schilling, Birgit, Gan, Li, Casaletto, Kaitlin B., and Tracy, Tara E.
- Subjects
Neurons ,Genetic engineering ,Protein kinases ,Advertising executives ,Alzheimer's disease ,Health care industry - Abstract
Synaptic plasticity is obstructed by pathogenic tau in the brain, representing a key mechanism that underlies memory loss in Alzheimer's disease (AD) and related tauopathies. Here, we found that reduced levels of the memory-associated protein KIdney/BRAin (KIBRA) in the brain and increased KIBRA protein levels in cerebrospinal fluid are associated with cognitive impairment and pathological tau levels in disease. We next defined a mechanism for plasticity repair in vulnerable neurons using the C-terminus of the KIBRA protein (CT-KIBRA). We showed that CT- KIBRA restored plasticity and memory in transgenic mice expressing pathogenic human tau; however, CT-KIBRA did not alter tau levels or prevent tau-induced synapse loss. Instead, we found that CT-KIBRA stabilized the protein kinase M[zeta] (PKM[zeta]) to maintain synaptic plasticity and memory despite tau-mediated pathogenesis. Thus, our results distinguished KIBRA both as a biomarker of synapse dysfunction and as the foundation for a synapse repair mechanism to reverse cognitive impairment in tauopathy., Introduction Pathological tau protein accumulates and forms aggregates in the brain in neurodegenerative diseases classified as tauopathies, including Alzheimer's disease (AD), Pick's disease, corticobasal degeneration (CBD) and progressive supranuclear palsy [...]
- Published
- 2024
- Full Text
- View/download PDF